| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | 209.7M | 10.60 | 195.57 | 0% | 0.00 | |||
| AFJKAimei Health Technology Co., Ltd | 281.66M | 46.01 | 164.32 | 3.35% | 0.00 | |||
| OACCWOaktree Acquisition Corp. III Life Sciences | 0.93 | 17.12 | 0.71% | 0.00 | ||||
| DMAADrugs Made In America Acquisition Corp. Ordinary Shares | 348.58M | 10.40 | -185.71 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Net Interest Income | 199.85K | 3.62M |
| NII Growth % | - | 17.1% |
| Net Interest Margin % | - | - |
| Interest Income | 199.85K | 3.62M |
| Interest Expense | 0 | 0 |
| Loan Loss Provision | 0 | 0 |
| Non-Interest Income | -199.85K | -3.62M |
| Non-Interest Income % | - | - |
| Total Revenue | 0 | 0 |
| Revenue Growth % | - | - |
| Non-Interest Expense | 28.46K | 1.06M |
| Efficiency Ratio | - | - |
| Operating Income | -28.46K | -1.06M |
| Operating Margin % | - | - |
| Operating Income Growth % | - | -36.42% |
| Pretax Income | 171.39K | 2.55M |
| Pretax Margin % | - | - |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | - | - |
| Net Income | 171.39K | 2.55M |
| Net Margin % | - | - |
| Net Income Growth % | - | 13.89% |
| Net Income (Continuing) | 171.39K | 2.55M |
| EPS (Diluted) | 0.02 | 0.28 |
| EPS Growth % | - | 13.74% |
| EPS (Basic) | 0.02 | 0.28 |
| Diluted Shares Outstanding | 9.03M | 9.03M |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash & Short Term Investments | 580.72K | 28.21K |
| Cash & Due from Banks | 580.72K | 28.21K |
| Short Term Investments | 0 | 0 |
| Total Investments | 0 | 73.78M |
| Investments Growth % | - | - |
| Long-Term Investments | 0 | 73.78M |
| Accounts Receivables | 0 | 0 |
| Goodwill & Intangibles | - | - |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| PP&E (Net) | 0 | 0 |
| Other Assets | 69.89M | 0 |
| Total Current Assets | 580.72K | 30.38K |
| Total Non-Current Assets | 69.89M | 73.78M |
| Total Assets | 70.47M | 73.81M |
| Asset Growth % | - | 0.05% |
| Return on Assets (ROA) | 0% | 0.04% |
| Accounts Payable | 0 | 0 |
| Total Debt | 0 | 227.7K |
| Net Debt | -580.72K | 199.49K |
| Long-Term Debt | 0 | 0 |
| Short-Term Debt | 0 | 227.7K |
| Other Liabilities | 690K | 690K |
| Total Current Liabilities | 24.84K | 816.99K |
| Total Non-Current Liabilities | 690K | 690K |
| Total Liabilities | 714.84K | 1.51M |
| Total Equity | 69.76M | 72.31M |
| Equity Growth % | - | 0.04% |
| Equity / Assets (Capital Ratio) | - | - |
| Return on Equity (ROE) | 0% | 0.04% |
| Book Value per Share | 7.73 | 8.01 |
| Tangible BV per Share | - | - |
| Common Stock | 69.89M | 73.78M |
| Additional Paid-in Capital | 0 | 0 |
| Retained Earnings | -134.34K | -1.48M |
| Accumulated OCI | 0 | 0 |
| Treasury Stock | 0 | 0 |
| Preferred Stock | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | 0 | -672.29K |
| Operating CF Growth % | - | - |
| Net Income | 171.39K | 2.55M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | -196.23K | -3.62M |
| Working Capital Changes | 24.84K | 392.5K |
| Cash from Investing | -69.69M | -277.7K |
| Purchase of Investments | -69.69M | 0 |
| Sale/Maturity of Investments | 0 | 0 |
| Net Investment Activity | - | - |
| Acquisitions | 0 | 0 |
| Other Investing | 0 | -277.7K |
| Cash from Financing | 70.27M | 397.48K |
| Dividends Paid | 0 | 0 |
| Share Repurchases | 0 | 0 |
| Stock Issued | 70.27M | 0 |
| Net Stock Activity | - | - |
| Debt Issuance (Net) | 0 | 277.7K |
| Other Financing | 70.27M | 119.78K |
| Net Change in Cash | 580.72K | -552.51K |
| Exchange Rate Effect | 0 | 0 |
| Cash at Beginning | 0 | 580.72K |
| Cash at End | 580.72K | 28.21K |
| Interest Paid | 0 | 0 |
| Income Taxes Paid | 0 | 0 |
| Free Cash Flow | 0 | -672.29K |
| FCF Growth % | - | - |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | 0.25% | 3.59% |
| Return on Assets (ROA) | 0.24% | 3.54% |
| Net Interest Margin | 0.28% | 4.9% |
| Equity / Assets | 98.99% | 97.96% |
| Book Value / Share | 7.73 | 8.01 |
| NII Growth | - | 1709.88% |
Aimei Health Technology Co., Ltd (AFJK) has a price-to-earnings (P/E) ratio of 164.3x. This suggests investors expect higher future growth.
Aimei Health Technology Co., Ltd (AFJK) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Aimei Health Technology Co., Ltd (AFJK) is profitable, generating $1.4M in net income for fiscal year 2024.
Aimei Health Technology Co., Ltd (AFJK) has a return on equity (ROE) of 3.6%. This is below average, suggesting room for improvement.
Aimei Health Technology Co., Ltd (AFJK) has a net interest margin (NIM) of 4.9%. This indicates healthy earnings from lending activities.
Aimei Health Technology Co., Ltd (AFJK) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.